Valsartan Salts

Abstract

The invention relates to new salts of valsartan or crystalline, also partly crystalline and amorphous salts of valsartan, the respective production and usage, and pharmaceutical preparations containing such a salt.

1 . A calcium salt of valsartan.  
     
     
         2 . A salt according to  claim 1  in crystalline, partially crystalline or amorphous form.  
     
     
         3 . The tetrahydrate of the calcium salt of valsartan according to  claim 1 .  
     
     
         4 . The tetrahydrate according to  claim 3 , characterised by 
 (i) an X-ray powder pattern taken with a Guinier camera comprising the following interlattice plane intervals:    d in [Å]: 16.1±0.3, 9.9±0.2, 9.4±0.2, 7.03±0.1, 6.50±0.1, 5.87±0.05, 5.74±0.05, 4.95±0.05, 4.73±0.05, 4.33±0.05, 4.15±0.05, 4.12±0.05, 3.95±0.05; or    (ii) an ATR-IR spectrum having the following absorption bands expressed in reciprocal wave numbers (cm −1 ):    1621 (st); 1578 (m); 1458 (m); 1441 (m); 1417 (m); 1364 (m); 1012 (m); 758 (m); 738 (m); 696 (m); 666 (m).    
     
     
         5 . A salt according to  claim 1  in the form of a solvate.  
     
     
         6 . A salt according to  claim 1  in the form of a hydrate.  
     
     
         7 . A salt according to  claim 1  in a form selected from the group consisting of 
 (i) a crystalline form;    (ii) a partly crystalline form;    (iii) an amorphous form; and    (iv) a polymorphous form.    
     
     
         8 . A pharmaceutical composition comprising a compound according to  claim 1  and a pharmaceutically acceptable excipient or additive.  
     
     
         9 . A pharmaceutical composition according to  claim 8 , containing a salt according to  claim 1  in combination with at least one composition selected from the group consisting of a: 
 (i) HMG-Co-A reductase inhibitor or a pharmaceutically acceptable salt thereof,    (ii) angiotensin converting enzyme (ACE) Inhibitor or a pharmaceutically acceptable salt thereof,    (iii) calcium channel blocker or a pharmaceutically acceptable salt thereof,    (iv) aldosterone synthase inhibitor or a pharmaceutically acceptable salt thereof,    (v) aldosterone antagonist or a pharmaceutically acceptable salt thereof,    (vi) dual angiotensin converting enzyme/neutral endopeptidase (ACE/NEP) inhibitor or a pharmaceutically acceptable salt thereof,    (vii) endothelin antagonist or a pharmaceutically acceptable salt thereof,    (viii) renin inhibitor or a pharmaceutically acceptable salt thereof, and    (ix) diuretic or a pharmaceutically acceptable salt thereof.    
     
     
         10 . A method for the treatment of diseases and conditions which can be inhibited by blocking the AT 1  receptor comprising administering a therapeutically effective amount of the compound of  claim 1  to a patient on need thereof.